Showing results (131-140 of 203) with videos related to
Sort By:
Pageof 21
Proceedings of the National Academy of Sciences of the United States of America|March 20, 2009
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potencyPaolo Ingallinella, Elisabetta Bianchi, Neal A Ladwa, et al.Bioorganic & Medicinal Chemistry Letters|March 1, 2006
Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutantEster Muraglia, Olaf D Kinzel, Ralph Laufer, et al.HIV Clinical Trials|February 23, 2016
Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT StudyDanielle P Porter, Jonathan Toma, Yuping Tan, et al.Antimicrobial Agents and Chemotherapy|March 18, 2009
Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitorMing-Tain Lai, Vandna Munshi, Sinoeun Touch, et al.Journal of Medical Primatology|April 30, 2005
SIV-specific T lymphocyte responses in PBMC and lymphoid tissues of SIV-infected pigtailed macaques during suppressive combination antiretroviral therapyLucy M Carruth, M Christine Zink, Patrick M Tarwater, et al.Journal of Hepatology|March 28, 2017
Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analysesTania M Welzel, Neeru Bhardwaj, Charlotte Hedskog, et al.The Journal of Biological Chemistry|September 19, 2002
Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine designJoseph G Joyce, William M Hurni, Michael J Bogusky, et al.American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 15, 2021
ALVR109, an off-the-shelf partially HLA matched SARS-CoV-2-specific T cell therapy, to treat refractory severe COVID-19 pneumonia in a heart transplant patient: Case reportKatalin Martits-Chalangari, Cedric W Spak, Medhat Askar, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|July 11, 2008
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutationEvguenia S Svarovskaia, Joy Y Feng, Nicolas A Margot, et al.JAMA|July 14, 2004
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trialJoel E Gallant, Schlomo Staszewski, Anton L Pozniak, et al.Pageof 21